원문정보
초록
영어
Therapeutic antibodies have been hot issues in both pharmaceutical industry and academia for more than a decade. The unique properties in specificity and high affinity toward their targets made them as most successful biological drugs at oncology and inflammatory diseases.
However, the development of antibody therapeutics has been challenging and complicated process, which became main hurdles for small pharmaceutical and biotech companies. Scripps Korea Antibody Institute (SKAI) is the first overseas branch institute of The Scripps Research
Institute (TSRI), which was founded 2009 at Chuncheon-si, Korea. Based on enormous experience on the antibody science from TSRI, SKAI will perform antibody-focused research programs, which will touch many issues at therapeutic antibody development. Details will be
presented with the brief introduction of SKAI.